3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
405
Brain Neoplasms
163
Glioma
159
Gliosarcoma
128
Astrocytoma
115
Central Nervous System Neoplasms
110
Oligodendroglioma
74
Neuroblastoma
44
Medulloblastoma
33
Ependymoma
26
Recurrence
23
Neoplasms
19
Neoplasm Metastasis
16
Diffuse Intrinsic Pontine Glioma
15
Choroid Plexus Neoplasms
13
Optic Nerve Glioma
11
Melanoma
11
Spinal Cord Neoplasms
10
Rhabdoid Tumor
10
Lymphoma
9
Familial ependymoma
9
Rhabdomyosarcoma
8
Osteosarcoma
8
Neuroectodermal Tumors, Primitive
8
Breast Neoplasms
8
Sarcoma, Ewing
6
Sarcoma
6
Pinealoma
6
Neuroectodermal Tumors, Primitive, Peripheral
6
Glioma, Subependymal
6
Interventions
vandetanib
2
Bevacizumab
2
Anthropogenic Effects
2
enzastaurin
1
carotuximab
1
Temozolomide
1
Tamoxifen
1
Steroids
1
Irinotecan
1
Carboplatin
1
Bortezomib
1
Blood Specimen Collection
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Temozolomide
×
CNS
×
Clear all
NCT02761070
2023-03-08
RE-GEND
Kyorin University
Phase 3
Unknown
146 enrolled